FLUMINE

Anti-inflammatory Injectable Solution for Horses & Cattle

Each milliliter of FLUMINE Injectable Solution contains flunixin meglumine equivalent to 50 mg flunixin.

Flunixin meglumine is a nonsteroidal anti-inflammatory drug not related to the corticosteroids, but pharmacologically related to phenylbutazone, aspirin, indomethacin or dipyrone, and the other NSAID (nonsteroidal anti-inflammatory) agents. It also has analgesic (pain-relieving) and antipyretic (fever-reducing) activity, which is secondary to its anti-inflammatory effect. The drug acts directly at the level of the tissues, not via a nervous system action. It acts primarily on inflamed tissues and is used for muscle or bone/joint diseases and in the treatment of colic pain.


INDICATION:

Horses:
FLUMINE Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.
Cattle:
FLUMINE Injectable Solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. FLUMINE Injectable Solution is also indicated for the control of inflammation in endotoxemia.

ACTIVE INGREDIENTS PER ML ACTION
Flunixin (as Flunixin Meglumine) 50 mg Anti-inflammatory.

NON-ACTIVE INGREDIENTS PER 100ML ACTION
Propylene Glycol 25% Buffer.
Water Q.S. Buffer.

ADMINISTRATION AND DOSAGE:
Horses:
The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL/100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. The recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur.
Cattle:
The recommended dose for cattle for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia is 1.1 to 2.2 mg/kg (0.5 to 1 mg/lb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg/kg (1.0 mg/lb) of body weight. Avoid rapid intravenous administration of the drug.
The recommended dose for acute bovine mastitis is 2.2 mg/kg (1 mg/lb: 2 mL per 100 lbs) of body weight given once by intravenous administration.

NOTE: For Veterinary Use Only

STORAGE:
Store between 15° to 30° C. Protect from light.

PRECAUTIONS:
The product should be stored between 2° and 30° C (36° and 86°F). DO NOT USE FOR MORE THAN FIVE CONSECUTIVE DAYS. This product is not intended for long-term use. If significant problems continue after the acute treatment period, consult your veterinarian for advice on further treatment or management techniques. Inadvertent intra-arterial (into an artery) injection can cause ataxia, incoordination, hyperventilation, agitation, and weakness.

To be effective, the full dose must be consumed. Most horses will readily accept the drug when mixed in with their regular feed. Feed must be “moist” (e.g., sweet feed or mash) to avoid the drug settling out to the bottom of the feed bin. For horses that will not take the medicated grain, try mixing the medication in a small amount of molasses and adding this mixture to the grain.

CAUTIONS:
As a class, cyclo-oxygenase inhibitory NSAID’s may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction.

Since many NSAID’s possess the potential to induce gastrointestinal ulceration, concomitant use of FULMINE Injectable Solution with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

Horse: The effect of FLUMINE Injectable Solution on pregnancy has not been determined. Studies to determine activity of FLUMINE Injectable Solution when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

Cattle:
Do not use in bulls intended for breeding, as reproductive effects of FLUMINE Injectable Solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. Do not exceed the recommended dose.

WARNING:
Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Not for use in horses intended for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in violative residues in the edible tissues of cattle sent to slaughter.

PRESENTATION:
100 ml in clear glass vial.

SPECIES: equine, livestock

REMARKS: VET ONLY PRODUCT

http://www.jaapharm.com


Request for a quote below: